USADA announced today that U.S. Track & Field athlete Ramon Clay, 35, of Miami, Florida, has accepted a two-year period of ineligibility for an anti-doping rule violation based on his use and possession of anabolic agents and hormones, and other substances during a period from 2000-2004.
Anabolic agents and hormones are prohibited substances under the USADA Protocol for Olympic and Paralympic Movement Testing and the anti-doping rules of the International Association of Athletics Federations (IAAF), both of which have adopted the World Anti-Doping Code (“Code”) and the World Anti-Doping Agency Prohibited List.
Clay’s two-year period of ineligibility began on November 9, 2009, the date USADA initiated formal proceedings against Clay. Additionally, Clay is disqualified from all competitive results achieved on and subsequent to January 1, 2000, the date he first committed the anti-doping rule violations based on evidence currently in USADA’s possession, including forfeiture of any medals, points and prizes.
In an effort to aid athletes, as well as all support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements as well as performance-enhancing and recreational drugs. In addition, the agency manages a drug reference hotline, Drug Reference Online (www.GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and proactively distributes a multitude of educational materials, such as the Prohibited List, easy-reference wallet cards, periodic newsletters, and protocol and policy reference documentation.
USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement, and is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.
For more information or media inquiries, click here.